ATI-1
ATI-1 is an autophagy initiation inhibitor. ATI-1 targets valosin-containing protein (VCP/p97, disrupts its interaction with UFL1, impairs UFMylation homeostasis associated with VCP, promotes polyubiquitination and degradation of Beclin1, and blocks the formation of early autophagosomes. ATI-1 induces synergistic death of autophagy-dependent malignant tumor cells under nutrient deprivation conditions, accompanied by decreased mitochondrial membrane potential, reduced ROS levels and lysosomal stress. ATI-1 exhibits anti-tumor efficacy in a pancreatic adenocarcinoma xenograft mouse model. ATI-1 can be used for the research of pancreatic adenocarcinoma and lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 1242983-93-2
- Formula: C16H14F2N2O2S3
- Molecular Weight:400.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
ATI-1 (10 μM; 20 h, plus 20 μM CQ final 4 h) potently inhibits autophagosome formation in HeLa cells[1].
ATI-1 (5-20 μM; 24 h, plus 10 μM for 2 h under EBSS starvation) inhibits autophagy initiation in HeLa cells by reducing Beclin1 protein levels and suppressing autophagosome formation, with dose-dependent reductions in LC3II levels at 5, 10, 20 μM over 24 h, and paradoxical LC3II accumulation under starvation that does not reflect functional autophagosome formation[1].
ATI-1 (5-20 μM; 48 h, plus CQ co-treatment) robustly inhibits autophagy initiation in autophagy-addicted NCI-H1299 and MIA PaCa-2 cells by reducing Beclin1 protein levels, with dose-dependent reductions in LC3II levels at 5, 10, 20 μM over 48 h, and suppressed autophagosome formation in MIA PaCa-2 cells when combined with CQ[1].
ATI-1 (20 μM; 48-72 h) selectively inhibits proliferation, clonogenic capacity, migration, and invasion of autophagy-addicted NCI-H1299 and MIA PaCa-2 cells, with greater potency than in less autophagy-dependent HeLa cells[1].
ATI-1 (30 μM; 24 h) disrupts the VCP-UFL1 interaction, reduces VCP UFMylation, weakens the VCP-Beclin1 interaction, and selectively impairs specific VCP cofactor interactions (VCP-ATXN3, VCP-NPLOC4) in HeLa cells[1].
ATI-1 (3.13-50 μM) directly binds to purified full-length VCP (Kd = 25.1 μM) and purified VCP N-terminal domain (Kd = 32.5 μM) with measurable affinity[1].
ATI-1 (20 μM; 48 h) induces G1-phase arrest but does not trigger significant apoptosis in autophagy-addicted NCI-H1299 and MIA PaCa-2 cells[1].
ATI-1 (5-10 μM; 2-24 h) exacerbates metabolic vulnerability of autophagy-addicted NCI-H1299 and MIA PaCa-2 cells under EBSS-induced nutrient deprivation, leading to non-apoptotic cell death, reduced mitochondrial membrane potential, lower ROS levels, and lysosomal stress, with 5 μM ATI-1 reducing cell viability by ~50-70% over 24 h when combined with starvation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa cells
-
Concentration:10 μM; 20 μM CQ (final 4 h)
-
Incubation Time:20 h; 4 h (CQ)
-
Result:Markedly reduced the number of autophagosomes per cell.
-
Cell Line:HeLa cells
-
Concentration:10 μM (with 10 μM CQ final 2 h); 5, 10, 20 μM; 20 μM; 10 μM (EBSS starvation)
-
Incubation Time:24 h; 24 h; 24 h; 2 h (EBSS starvation)
-
Result:Prevented LC3II accumulation seen in the CQ-only group at 10 μM for 24 h with 10 μM CQ for the final 2 h.
Induced a dose-dependent reduction in LC3II levels at 5, 10, 20 μM for 24 h.
Reduced Beclin1 protein levels at 20 μM for 24 h.
Caused a paradoxical accumulation of LC3II under EBSS starvation at 10 μM for 2 h, but autophagic flux analysis confirmed reduced LC3 puncta.
-
Cell Line:NCI-H1299 cells, MIA PaCa-2 cells
-
Concentration:5, 10, 20 μM (NCI-H1299); 10 μM (NCI-H1299, with 10 μM CQ final 2 h); 5, 10, 20 μM (MIA PaCa-2); 10 μM (MIA PaCa-2, with 10 μM CQ final 2 h); 10 μM (MIA PaCa-2, with 20 μM CQ final 6 h); 20 μM (NCI-H1299, MIA PaCa-2)
-
Incubation Time:48 h (NCI-H1299); 48 h (NCI-H1299, plus 2 h CQ); 48 h (MIA PaCa-2); 48 h (MIA PaCa-2, plus 2 h CQ); 48 h (MIA PaCa-2, plus 6 h CQ); 48 h (NCI-H1299, MIA PaCa-2)
-
Result:Induced a dose-dependent reduction in LC3II levels in both NCI-H1299 and MIA PaCa-2 cells over 48 h.
Significantly reduced LC3II levels in MIA PaCa-2 cells at 10 μM for 48 h with 10 μM CQ for the final 2 h, with less pronounced effect in NCI-H1299 cells.
Reduced yellow autophagosome/autolysosome puncta in MIA PaCa-2 cells at 10 μM for 48 h with 20 μM CQ for the final 6 h compared to CQ alone.
Markedly decreased Beclin1 protein levels in both cell lines at 20 μM for 48 h.
-
Cell Line:NCI-H1299 cells, MIA PaCa-2 cells, HeLa cells
-
Concentration:20 μM
-
Incubation Time:72 h (CCK-8); 48 h (colony formation, wound healing, Transwell assays)
-
Result:Showed more pronounced growth-inhibitory effects in NCI-H1299 and MIA PaCa-2 cells than in HeLa cells, with lower IC50 values across time points.
Significantly inhibited proliferation of NCI-H1299 and MIA PaCa-2 cells at 20 μM for 48 h, while HeLa cells remained relatively resistant.
Markedly abrogated long-term clonogenic capacity and significantly impaired migratory and invasive potential of NCI-H1299 and MIA PaCa-2 cells.
-
Cell Line:NCI-H1299 cells, MIA PaCa-2 cells
-
Concentration:20 μM
-
Incubation Time:48 h
-
Result:Led to G1-phase arrest in both cell lines.
Did not induce obvious apoptosis, with no significant increase in apoptotic populations compared to controls.
-
Cell Line:NCI-H1299 cells, MIA PaCa-2 cells
-
Concentration:20 μM
-
Incubation Time:12 h, 24 h, 48 h
-
Result:Did not increase γH2AX levels at any time point.
Had little effect on ATXN3 abundance, unlike the canonical VCP inhibitor NMS-873 which induced robust γH2AX and reduced ATXN3 levels.
-
Cell Line:NCI-H1299 cells, MIA PaCa-2 cells
-
Concentration:10 μM (LC3, ROS, lysosomal, mitochondrial assays); 5 μM (cell viability, apoptosis assays)
-
Incubation Time:2 h (LC3, ROS, lysosomal, mitochondrial assays); 24 h (cell viability, apoptosis assays)
-
Result:Enhanced LC3II accumulation compared to EBSS alone when co-treated with ATI-1 and EBSS.
Reduced cell viability by ~50% within 24 h at 5 μM, and up to ~70% in MIA PaCa-2 cells.
No significant increase in apoptotic populations was observed.
Decreased mitochondrial membrane potential, reduced ROS levels, and caused lysosomal stress with impaired membrane integrity and reduced acidic staining when combined with EBSS.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Significantly suppressed tumor growth, resulting in reduced final tumor weights and volumes compared to controls.
Markedly reduced intratumoral LC3 and Ki-67 expression.
Caused no significant body weight loss or pathological abnormalities in major organs (heart, liver, spleen, lungs, kidneys).
Chemical Information
-
CAS No. 1242983-93-2
-
Molecular Weight 400.49
-
Formula C16H14F2N2O2S3
-
SMILES
FC1=CC(F)=CC(NS(=O)(C2=CC=C(C3=NC(C(C)C)=CS3)S2)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)